Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended31 December, 2023 (the "Reporting Period") and the information currently available to the Board,it...
First International Shipment of HANSIZHUANG Launched
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying anti-PD-1 mAb Zerpidio® (serplulimab, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of benefiting patients worldwide with high-quality biopharmaceuticals...
HANSIZHUANG Sets Sail in Indonesia Market
* The 1st China anti-PD-1 monoclonal antibody successfully approved in Southeast Asia - * The 1st overseas approval of HANSIZHUANG, highlighting another major milestone of Henlius' global strategy after HANQUYOU - * Along with KGbio and other partners to develop and launch HANSIZHUANG in ov...
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for patients with...
Henlius Announces NMPA Approvals of Two ADC Candidates for IND
SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the investigational new drug (IND) applications of HLX42 for Injection, a novel EGFR-targeting antibody-drug conjugate (ADC) as well as HLX43, a novel PD-L1-targeting ADC, have been approved by the Na...
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India
* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerc...
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India
* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerci...
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth
SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits ofRMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products. HANQUYOU (trast...
Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues
SHANGHAI, April 1, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 annual results. In 2022, Henlius' revenue reached aboutRMB3.2147 billion, representing an increase of 91.1% YoY, primarily due to sales revenue and licensing revenue generated by the successive commercialisation of vario...
EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab)
* HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) * The EC and the FDA previously granted Orphan Drug Designations (ODDs) for HANSIZHUANG in SCLC * HANSIZHUANG is approved in China for microsatellite instability-high (MSI-H)...
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US
SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial inthe United States comparing HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently develo...
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC
SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-lin...
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
* Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - * Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights - * Palleon receives u...
Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer
SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the United States Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for HANSIZHUANG (serplulimab) for the treatment of small cell lung cancer (SCLC). This is the first such d...
Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG
SHANGHAI, March 25, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG (generic name: serplulimab injection) has been approved by the National Medical Products Administration (NMPA)for the treatment of adult ...
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma
SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma
SHANGHAI, March 16, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year endedDecember 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, afford...
Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population
* The ASTRUM-005 states that serplulimab combined with carboplatin-etoposide prolonged median OS in both the overall population and the Asian subgroup, the median overall survival (OS) in the serplulimab and placebo groups were 15.38 and 11.10 months, respectively, reducing risk of death by 38%...
Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration
SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of meta...
